Ahead of the 2026 ASCO Annual Meeting, organizers lifted the pre-meeting embargo on May 21 and highlighted multiple trial readouts across lung, gastrointestinal, and genitourinary cancers. The preview includes the CHALLENGE cost-utility analysis in resected colon cancer, KEYNOTE-B15/EV-304 in perioperative urothelial carcinoma, and CHRYSALIS-2 for atypical EGFR-mutant NSCLC cohorts. In CHALLENGE’s economic evaluation, a 3-year structured exercise program delivered dominance over health education materials in a Canadian public payer base case, with lower total costs and higher QALYs over a 5-year horizon. The analysis reported dominance in 49% of bootstrap samples and 79% of iterations below a $50,000 per-QALY willingness-to-pay threshold. For clinicians and health-system decision-makers, the pre-ASCO emphasis on payer-relevant outcomes signals broader scrutiny of non-drug interventions and perioperative strategies as part of standard-of-care.